Spero Therapeutics, Inc. (NASDAQ:SPRO) Shares Acquired by Mackenzie Financial Corp

Mackenzie Financial Corp grew its position in shares of Spero Therapeutics, Inc. (NASDAQ:SPRO - Free Report) by 487.9% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 187,559 shares of the company's stock after purchasing an additional 155,656 shares during the period. Mackenzie Financial Corp owned approximately 0.34% of Spero Therapeutics worth $193,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in the company. Prudential Financial Inc. purchased a new position in shares of Spero Therapeutics in the fourth quarter valued at approximately $51,000. Virtu Financial LLC purchased a new position in Spero Therapeutics in the 4th quarter valued at approximately $47,000. Jane Street Group LLC purchased a new position in Spero Therapeutics in the 4th quarter valued at approximately $54,000. Renaissance Technologies LLC grew its stake in shares of Spero Therapeutics by 13.4% in the fourth quarter. Renaissance Technologies LLC now owns 1,105,591 shares of the company's stock worth $1,139,000 after acquiring an additional 130,938 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its stake in shares of Spero Therapeutics by 26,011.9% in the fourth quarter. JPMorgan Chase & Co. now owns 61,624 shares of the company's stock worth $63,000 after acquiring an additional 61,388 shares in the last quarter. 25.60% of the stock is currently owned by institutional investors and hedge funds.

Spero Therapeutics Price Performance

Shares of NASDAQ SPRO traded up $0.26 during mid-day trading on Monday, hitting $2.76. The company had a trading volume of 3,990,005 shares, compared to its average volume of 1,117,770. The company has a market capitalization of $154.31 million, a PE ratio of 39.43 and a beta of 1.31. The business's 50-day simple moving average is $0.96 and its 200 day simple moving average is $0.93. Spero Therapeutics, Inc. has a 1-year low of $0.51 and a 1-year high of $2.95.

Spero Therapeutics (NASDAQ:SPRO - Get Free Report) last issued its quarterly earnings results on Tuesday, May 13th. The company reported ($0.25) earnings per share for the quarter, topping the consensus estimate of ($0.55) by $0.30. The company had revenue of $5.87 million for the quarter, compared to the consensus estimate of $11.00 million. Spero Therapeutics had a return on equity of 4.03% and a net margin of 3.30%. On average, analysts expect that Spero Therapeutics, Inc. will post -1.2 EPS for the current year.

About Spero Therapeutics

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.